The Next Big Thing in Biotech
Nov 02, 2012 | 6:00 AM EDT - 
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

Columnist Conversations

View Chart »  View in New Window » I like GDX on the buy side as long as we can hold ab...
First off, GILD was an unmitigated disaster, we cut this and ran. this is ugly here, we'll take this off...
I sold part of my Crane Corp (CR) position today as better than expected Q2 earnings sent the shares to a new ...
So can National Oilwell Varco (NOV).  I've added to the position.  Nothing much has changed since my...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.